BridgeBio reports infigratinib Phase 3 data
BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.
BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.
Bhutan has transferred about 400 Bitcoin (CRYPTO:BTC), worth roughly US$30.62 million, to an unlabelled external address.
CleanSpark has produced 593 Bitcoin (CRYPTO:BTC) in August while selling 821 BTC during the month.
Canary Capital has launched the first US-listed staked TRON ETF, giving investors exposure to TRON (CRYPTO:TRX) through traditional brokerage accounts.
ASE Technology Holding (NYSE:ASX) reported unaudited consolidated net revenues of NT$82.25 billion for August 2026, increasing 45.7% year over year and 11.5% from July 2026.
Gemini has secured a Major Payment Institution licence in Singapore through its local entity, Gemini Digital Payments Singapore.
Iran has eased foreign-exchange controls, allowing businesses to use cryptocurrency for cross-border export payments.
Capstone Copper (ASX:CSC) recorded a 3.6% share price increase after copper prices hit record highs for two consecutive sessions.
Plattsburgh, New York, has proposed a 12-month moratorium on new and expanded high-energy computing facilities using at least 300 kilowatts.
Red Sky Energy (ASX:ROG) will participate in the Yarrow North 1 well re-entry programme in South Australia.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy